From limp to leaps: toddler's cancer battle inspires $1.7M research push

Kelly Hennessy noticed something odd about the way her daughter moved. Mileah, not yet three, had developed a peculiar skip—long-legged and ungainly—that her mother initially chalked up to imitation of a favorite cousin. The girl was bright and active, the kind of child who thrived outdoors and in the company of her close family. When the daycare mentioned that Mileah had been dragging one side of her body after a minor fall, Hennessy assumed a sprain and moved up her daughter's doctor's appointment.

The X-ray showed a large dark mass around Mileah's left knee and femur. A pediatrician offered two possibilities: infection or tumor. Hennessy spent a week in the hospital while her daughter underwent investigations. The first biopsy came back inconclusive. Two weeks later, after a second biopsy, the diagnosis arrived: osteosarcoma, a rare and aggressive bone cancer. Because of Mileah's age and the tumor's location, amputation was already being discussed as a necessary step.

"I couldn't even process the X-ray, let alone everything else that was still coming to me," Hennessy recalled. Within days, Mileah had a central line placed and began chemotherapy. The treatment was punishing. She developed fevers, vomiting, and mucositis—severe inflammation of the mouth and throat. She was hospitalized repeatedly for infections. Her chemotherapy regimen included doxorubicin, a drug so toxic it carries the nickname "the red devil." After two cycles, Mileah traveled to Melbourne with her orthopedic surgeon for a Van Ness rotationplasty, an unusual limb-salvage procedure in which part of the leg is removed, the foot rotated 180 degrees, and reattached to the thigh. Her heel would function as a knee joint inside a prosthetic leg.

The hardest part came after surgery, when Mileah returned to Sydney and her body deteriorated under continued chemotherapy. Infections multiplied. She was connected to multiple drips for medication and pain management. The ordeal consumed the family's life. Hennessy stopped working and faced mounting financial pressure. Friendships shifted. Her relationship broke down. She focused entirely on getting her daughter through treatment, while life's ordinary demands—bills, relationships, work—continued pressing from the outside. "Life still goes on," she reflected. "You've got your financial issues because you're not working. There's all these little things that still are going on around the outside but your focus is just on making sure your kid gets better."

Hennessy tried to make the experience comprehensible to her young daughter. "You've got a leg that's very sick, we need to get it better, we've got to give you special medicine but then we're going to give you a new leg," she told Mileah. Now approaching her fifth birthday, Mileah has finished treatment and is thriving. She attends preschool and will start kindergarten next year. She is on her third prosthetic leg as her body grows. She walks almost normally and is working on running and riding a bike. When her pants are on, most people cannot tell she is an amputee. Her latest lung scans, part of her regular cancer monitoring, came back clear. Mileah shows more interest in choosing colorful patterns for her prosthetics—mermaids, Barbie, Disney characters—than in dwelling on what she endured. Her young age may mean she will never remember the worst of it.

Mileah's recovery has become a catalyst for broader change. Her family is now sharing her story to encourage corporate investment in cancer research. The 2025 Dare to Cure events in Sydney and Melbourne raised $1.7 million, funding the equivalent of sixteen senior researchers. The program, run by the Children's Cancer Institute, challenges business leaders and executives to step outside their comfort zones while raising money for childhood cancer research. Australia's government has also committed $5 million to support participation in the LifeArc Worldwide CAR-T Pathfinder Trial and Paediatric Cell Therapy Accelerator, part of a $300 million investment in the Australian Cancer Research Program announced in 2026. CAR-T is a type of immunotherapy that re-engineers a patient's white blood cells to destroy cancer cells. Health Minister Mark Butler said the funding would "help bring world-class international CAR-T clinical trials closer to home for Australian children and young people with cancer."

Professor Brendan Murphy, chair of Children's Cancer CoLab, welcomed the announcement. The CoLab reports that one thousand Australian children are diagnosed with cancer every year, three children die from the disease every week, and eighty percent of survivors experience long-term effects from their treatment. For Hennessy, the challenge events offer something beyond fundraising. Children facing cancer are pushed outside their comfort zones constantly—through scans, chemotherapy, surgeries, hospital stays. She believes asking people who have been spared that reality to challenge themselves, even briefly, can build empathy while raising vital funds. "These kids are getting put out of their comfort zone every single day, 24-7," she said. "To have such an amazing campaign where you can have a laugh and raise money at the same time and also watch people being put out of their comfort zone in a safe and welcome environment, I think makes a huge difference."